Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
425 results
  • Pharmacogenetics of alcohol addiction: current perspectives. [Journal Article]
    Appl Clin Genet 2019; 12:131-140Zastrozhin MS, Skryabin VY, … Sychev DA
  • Genetics of alcohol addiction is currently a contradictive and complex field, where data in the most studies reflect methods' limitations rather than meaningful and complementary results. In our review, we focus on the genetics of alcohol addiction, leaving genetics of acute alcohol intoxication out of the scope. A review of the literature on pharmacogenetic biomarkers development for the pharmac…
  • Drinking Levels and Profiles of Alcohol Addicted Rats Predict Response to Nalmefene. [Journal Article]
    Front Pharmacol 2019; 10:471Foo JC, Vengeliene V, … Spanagel R
  • CONCLUSIONS: Our results suggest that nalmefene reduces alcohol intake during a relapse-like situation but effectiveness can differ greatly at the individual level. However, who responds may be informed by examining drinking profiles and rats that show high drinking levels prior to treatment are more likely to respond to nalmefene.
  • Selecting an appropriate alcohol pharmacotherapy: review of recent findings. [Journal Article]
    Curr Opin Psychiatry 2019; 32(4):266-274Castrén S, Mäkelä N, Alho H
  • CONCLUSIONS: Three new published RCTs focus on baclofen and naltrexone. These results are consistent with old findings demonstrating that naltrexone reduces heavy drinking. Several RCT on baclofen do not support the use of baclofen for treatment of AUD. Encouraging results have been reported for topiramate, gabapentin and also varenicline, which might be useful in patients with comorbid nicotine dependence.
  • Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. [Journal Article]
    J Pharmacol Exp Ther 2019Krieter P, Gyaw S, … Skolnick P
  • The dramatic rise in overdose deaths linked to synthetic opioids (e.g., fentanyl, carfentanil) may require more potent, longer duration opiate antagonists than naloxone. Both the high affinity of nalmefene at μ opiate receptors and its long half-life led us to examine the feasibility of developing an intranasal (IN) formulation as a rescue medication that could be especially useful in treating sy…
New Search Next